| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1cd7029ec038fa78d4b371f9bf08e9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a06c98b317ba821e9d90a0374efcfdc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed8d0b3ef3b3e32dff34d1a0cb2a06f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41b561a1edb1f4f3b3a7f80ee639b6b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7c7e12fe34816b7081b4fa91b14a69dc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_848e1c1419b0ce4b54b205ce44773994 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2011-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2014-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4e5897df5b875c4641057e827a6d3c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6607f835d2283c4a27eb62d3a52ba147
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af5d371040719a22dfedacf19608fa45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97ee785d2935a06454b4329fd8f3b9c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2894cb81483e813fe45cf2cea60c8a5 |
| publicationDate |
2014-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8679743-B2 |
| titleOfInvention |
Reducing IRF4, DUSP22, or FLJ43663 polypeptide expression |
| abstract |
This document relates to the activity of interferon regulatory factor 4 (IRF4) in T-cell lymphomas. For example, methods and materials involved in reducing the expression of an IRF4 polypeptide in T-cell lymphoma cells and identifying agents having the ability to reduce expression of an IRF4 polypeptide in T-cell lymphoma cells are provided. This document also relates to reducing DUSP22 or FLJ43663 polypeptide activity in T-cell lymphomas. For example, methods and materials involved in reducing the expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells and identifying agents having the ability to reduce expression of DUSP22 polypeptides and/or FLJ43663 polypeptides in T-cell lymphoma cells are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11241451-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019169219-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111886011-A |
| priorityDate |
2009-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |